Skandinaviska Enskilda Banken Ab (Publ) Cabaletta Bio, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $21.5 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding CABA
# of Institutions
127Shares Held
47.9MCall Options Held
202KPut Options Held
110K-
Jennison Associates LLC5.63MShares$15.4 Million0.02% of portfolio
-
Black Rock Inc. New York, NY4.76MShares$13 Million0.0% of portfolio
-
Fred Alger Management, LLC New York, NY4.12MShares$11.3 Million0.1% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.67MShares$10.1 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.04MShares$8.32 Million0.03% of portfolio
About Cabaletta Bio, Inc.
- Ticker CABA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,014,000
- Market Cap $79.5M
- Description
- Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...